Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy VBI Vaccines stock

Learn how to easily invest in VBI Vaccines stock.

VBI Vaccines Inc is a biotechnology business based in the US. VBI Vaccines shares (VBIV) are listed on the NASDAQ and all prices are listed in US Dollars. VBI Vaccines employs 127 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in VBI Vaccines

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – VBIV – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

VBI Vaccines stock price (NASDAQ: VBIV)

Use our graph to track the performance of VBIV stocks over time.

VBI Vaccines shares at a glance

Information last updated 2022-01-23.
Latest market close$1.53
52-week range$1.74 - $4.83
50-day moving average $2.47
200-day moving average $3.00
Wall St. target price$7.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.26

Buy VBI Vaccines shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
M1 Finance
Stocks
$0
0%
Free 1-year trial of M1 Plus
when you sign up for M1 Finance
Invest in your favorite stocks or in curated portfolios with automatic rebalancing.
SoFi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$0
$1 per month
$5
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Public
Stocks, ETFs, Cryptocurrency
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy VBI Vaccines stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

VBI Vaccines price performance over time

Historical closes compared with the close of $1.53 from 2022-01-27

1 week (2022-01-21) -12.07%
1 month (2021-12-28) -30.77%
3 months (2021-10-28) -49.00%
6 months (2021-07-28) -50.16%
1 year (2021-01-28) -53.07%
2 years (2020-01-28) 8.51%
3 years (2019-01-28) 1.54
5 years (2017-01-27) 3.8

VBI Vaccines financials

Revenue TTM $714,000
Gross profit TTM $-8,107,000
Return on assets TTM -18.1%
Return on equity TTM -40.7%
Profit margin 0%
Book value $0.62
Market capitalisation $447.7 million

TTM: trailing 12 months

VBI Vaccines share dividends

We're not expecting VBI Vaccines to pay a dividend over the next 12 months.

Have VBI Vaccines's shares ever split?

VBI Vaccines's shares were split on a 1:40 basis on 1 May 2016. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your VBI Vaccines shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for VBI Vaccines shares which in turn could have impacted VBI Vaccines's share price.

VBI Vaccines share price volatility

Over the last 12 months, VBI Vaccines's shares have ranged in value from as little as $1.74 up to $4.83. A popular way to gauge a stock's volatility is its "beta".

VBIV.US volatility(beta: 1.85)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while VBI Vaccines's is 1.8454. This would suggest that VBI Vaccines's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

VBI Vaccines overview

VBI Vaccines Inc. , a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901.

Frequently asked questions

What percentage of VBI Vaccines is owned by insiders or institutions?
Currently 0.524% of VBI Vaccines shares are held by insiders and 47.569% by institutions.
How many people work for VBI Vaccines?
Latest data suggests 127 work at VBI Vaccines.
When does the fiscal year end for VBI Vaccines?
VBI Vaccines's fiscal year ends in December.
Where is VBI Vaccines based?
VBI Vaccines's address is: 222 Third Street, Cambridge, MA, United States, 02142
What is VBI Vaccines's ISIN number?
VBI Vaccines's international securities identification number is: CA91822J1030
What is VBI Vaccines's CUSIP number?
VBI Vaccines's Committee on Uniform Securities Identification Procedures number is: 91822J103

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site